112227-09-5

Upstream product

• 133333-27-4 tert-butyl (1S)-1-[(2S)-5-oxotetrahydrofuran-2-yl]-2-phenylethylcarbamate 
• 136944-72-4 (S)-5-((R)-2-Cyclohexyl-1-hydroxy-ethyl)-dihydro-furan-2-one 
• 137271-78-4 Trifluoro-methanesulfonic acid (4S,5R)-5-cyclohexylmethyl-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester 
• 137530-20-2 Methanesulfonic acid (R)-2-cyclohexyl-1-((S)-5-oxo-tetrahydro-furan-2-yl)-ethyl ester 
• 137271-79-5 3-((4S,5R)-5-Cyclohexylmethyl-2,2-dimethyl-[1,3]dioxolan-4-yl)-propionic acid tert-butyl ester 
• 137271-77-3 ((4S,5R)-5-Cyclohexylmethyl-2,2-dimethyl-[1,3]dioxolan-4-yl)-methanol 
• 16666-81-2 cyclohexyltriphenylphosphorane 
• 98105-42-1 (S)-2-(t-butoxycarbonylamino)-3-cyclohexyl-1-propanal 
• 54848-33-8 (S)-tetrahydro-5-oxo-2-furancarbonyl chloride 
• 21461-84-7 (2S)-tetrahydro-5-oxofuran-2-carboxylic acid 
• 117997-58-7 (S)-4-Cyclohexylmethyl-5-formyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 
• 127772-89-8 (S)-5-tert-Butoxycarbonylamino-6-cyclohexyl-4-oxo-hexanoic acid ethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 125218-53-3 (5S,1'S)-5-(1'-azido-2'-cyclohexylethyl)dihydrofuran-2(3H)-one 

Downstream Products

• 112227-10-8 2S,4S,5S-6-Cyclohexyl-5-(t-butoxycarbonylamino)-2-(2-methyl-2-propenyl)-gamma-hexanolactone 
• 112228-21-4 2R,4S,5S-6-cyclohexyl-5-(t-butoxycarbonylamino)-2-(2'-methyl-2'-propenyl)-gamma-hexanolactone 
• 178049-22-4 5(S)-[1(S)-(Boc-amino)-2-cyclohexylethyl]-3(R)-(2,3,4-trimethoxyphenylmethyl)dihydrofuran-2-(3H)-one 
• 112227-93-7 5(S)-[1(S)-(Boc-amino)-2-cyclohexylethyl]-3(R)-[(p-methoxyphenyl)methyl]dihydrofuran-2-(3H)-one 
• 138498-90-5 3(R)-[(4-benzyloxyphenyl)methyl]-5(S)-[1(S)-(Boc-amino)-2-cyclohexylethyl]dihydrofuran-2-one 
• 112227-94-8 2R,4S,5S-6-Cyclohexyl-5-(t-butoxycarbonylamino)-2-(3,4-dichlorobenzyl)-gamma-hexanolactone 
• 112227-41-5 2R,4S,5S-6-Cyclohexyl-5-(t-butoxycarbonylamino)-2-benzyl-gamma-hexanolactone 
• 112227-92-6 2R,4S,5S-6-Cyclohexyl-5-(t-butoxycarbonylamino)-2-(p-methylbenzyl)-gamma-hexanolactone 
• 125016-06-0 (3S,5S)-5-[(1S)-1-(N-t-butoxycarbonylamino)-2-cyclohexylethyl]-3-(1-hydroxycyclohexyl)dihydrofuran-2(3H)-one 
• 127772-94-5 Oxalic acid 1-[(3S,5S)-5-((S)-1-tert-butoxycarbonylamino-2-cyclohexyl-ethyl)-2-oxo-tetrahydro-furan-3-yl]-1-methyl-ethyl ester methyl ester 
• 127772-92-3 [(S)-2-Cyclohexyl-1-((S)-4-isopropylidene-5-oxo-tetrahydro-furan-2-yl)-ethyl]-carbamic acid tert-butyl ester 
• 124032-36-6 (3S,5S)-5-[(1S)-1-(t-butoxycarbonyl)amino-2-cyclohexylethyl]-3-isopropyldihydrofuran-2(3H)-one 
• 123580-22-3 [(S)-2-Cyclohexyl-1-((2S,4R)-4-isopropyl-5-oxo-tetrahydro-furan-2-yl)-ethyl]-carbamic acid tert-butyl ester 
• 112228-22-5 2R,4S,5S-6-Cyclohexyl-5-(t-butoxycarbonylamino)-2-(2-methylpropyl)-gamma-hexanolactone 

Relevant academic research and scientific papers

Enantioselective synthesis of N-Boc-2,2-dimethyloxazolidine-5-carbaldehydes, versatile precursors of dipeptide isosteres

Highly enantioenriched cis and trans N-Boc-2,2-dimethyl-oxazolidine-5-carbaldehydes have been efficiently prepared from N-Boc-3-amino-1,2-alkanediols, readily available in enantiopure or enantioenriched form by Sharpless epoxidation methodology. These compounds have been converted into N-Boc-(S)-γ-[(S)-1-aminoalkyl]-γ-lactones which are key intermediates of hydroxyethylene dipeptide isosteres.

5-amino-4-hydroxyhexanoic acid derivatives

Compounds of formula I STR1 or their hydroxy-protected derivatives, and compounds of formula I' STR2 wherein T is an acyl radical of formula Z STR3 wherein Rz is unsubstituted or substituted hydrocarbyl wherein at least one carbon atom has been replaced by a hetero atom with the proviso that a hetero atom is not bonded directly to the carbonyl to which the radical Rz is bonded, alkyl having two or more carbon atoms, lower alkenyl, lower alkynyl, aryl or unsubstituted or substituted amino, and wherein the radicals R1, B1, R2, R3, A1, A2 and NR4 R5 are as defined in the description, and precursors thereof, are described. The compounds have pharmaceutical activity, for example in the treatment of retroviral diseases, such as AIDS.

ANTIVIRAL ETHERS OF ASPARTATE PROTEASE SUBSTRATE ISOSTERES

Antiretroviral compounds (which are effective, for example, against HIV) of the formula I STR1 in which R 1 is an acyl radical lower-alkoxyl-lower-alkanoyl whose lower alkoxy radical is unsubstituted or is substituted by halogen, phenyl, lower alkoxy or a heterocyclic radical selected from piperidinyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, thiazolidinyl, thiazolyl, indolyl or 4H-1-benzopyranyl which is unsubstituted or substituted by oxo, hydroxyl, amine, lower alkyl, lower-alkoxycarbonyl and/or phenyl-lower-alkoxycarbonyl; lower alkanoyl which is unsubstituted or is substituted by one of the said unsubstituted or substituted heterocyclic radicals; arylcarbonyl or heterocyclylcarbonyl which are substituted by heterocyclyl or heterocyclyl-lower-alkyl; phenyl-lower-alkanoyl which is substituted by hydroxyl and lower alkyl; or arylsulfonyl;or the residue of an amino acid which is defined in accordance with the description (and which may be acylated on the amino nitrogen by one of the abovementioned acyl radicals);R 2 and R 3 are in each case cyclohexyl, cyclohexenyl, phenyl, naphthyl or tetrahydronaphthyl which are unsubstituted or substituted by lower alkyl, phenyl, cyanophenyl, phenyl-lower-alkyl, halogen, halo-lower-alkyl, cyano, hydroxyl, lower alkoxy, phenyl-lower-alkoxyl, pyridyl-lower-alkoxy, lower-alkoxy-lower-alkoxy, lower-alkoxycarbonyl-lower-alkoxy, carboxyl-lower-alkoxy, hydroxyl-lower-alkoxy, carbamoyl-lower-alkoxy, cyano-lower-alkoxy, and phenyl-lower-alkanesulfonyl which is unsubstituted or substituted by halogen;R 4 is lower alkyl, cyclohexyl or phenyl; and R 5 is lower alkyl; and n is 1 or 2, or salts thereof, are novel.

Use of compositions for combating tumour diseases

The present invention relates to the use of inhibitors of HIV aspartate proteases, such as HIV-1- or HIV-2-protease, and their salts and to prodrugs for inhibiting the growth of tumors, especially those tumors which do not respond to the inhibition of HIV

RENIN-INHIBITORY OLIGOPEPTIDES, THEIR PREPARATION AND USE

Compounds of formula (I): STR1 A is a carbon-carbon bond or C 1-C 3 alkylene; B is imino group or C 1-C 2 alkylene; R 1 is C 1-C 4 alkyl, C 1-C 4 alkoxy, heterocyclic or optionally substituted amino; R 2 is optionally substituted phenyl or optionally substituted naphthyl; R 3 is thiazolyl, isoxazolyl or imidazolyl; R 4 is isopropyl or cyclohexyl; R 5 and R 6 are C. sub.1-C 4 alkyl, or, together with the carbon atom to which they are attached, C 3-C 7 cycloalkyl; R. sup.7 is hydrogen, optionally substituted C 1-C 6 alkyl group; and R 8 is hydrogen or C. sub.1-C 4 alkyl. These compounds have renin-inhibitory and, hence, hypotensive activities. The invention also provides a method for the treatment or prophylaxis of hypertension induced by failures in the renin-angiotensin system.

HIV protease inhibitors useful for the treatment of aids

Compounds of the form,ψ ψ A-G-Jψ ψ wherein A is an amine protecting group or urethane, G a dipeptide isostere and J a small terminal group are described. They are distinguished by tetrahydrofuryl or tetrahydropyranyl substituents, and the like. These compounds are useful in the inhibition of HIV protease, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.ψ

Studies of HIV-1 protease inhibitors. II. Incorporation of four types of hydroxyethylene dipeptide isosteres at the scissile site of substrate sequences

Human immunodeficiency virus type 1 (HIV-1) protease inhibitors containing four types of hydroxyethylene dipeptide isosteres were designed and synthesized. These inhibitors consist of eight stereoisomers of phenylalanylproline (Phe-Ψ[H.E.]-Pro), four ster

HIV protease inhibitors having polyether substituents

[From equivalent EP0487270A2] Polyether derivatives of the form, A-G-B-B-J ψ wherein G is a dipeptide isostere substituted with a polyether, B an amino acid or analog thereof, and J a small terminal group are described. These compounds are useful in the inhibition of DIV protease, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.ψ

A new enantioseletive synthesis of (4S, 5S)-5-(N-Boc)-amino-6-cyclohexyl-4-hydroxy-hexanoic acid lactone, a hydroxyethylene dipeptide isostere precursor

A new enantioselective synthesis of a valuable hydroxyethylene dipeptide isostere precursor, (4S,5S)-5-(N-Boc)-amino-6-cyclohexyl-4-hydroxy-hexanoic acid lactone, has been developed by using coupling reaction of chiral triflates as a key step.